Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20785606 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL29964264 | 0.83 | CYP2D6 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6OPRM1 | |
| SCHEMBL22917840 | 0.80 | OPRM1 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL20785729 | 0.80 | OPRM1 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL19261776 | 0.76 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL26957500 | 0.76 | CYP2D6 (0.61) | KCNH2CYP2D6OPRM1 | |
| SCHEMBL14625431 | 0.74 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL14144537 | 0.74 | OPRM1 (0.44) | SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL19261820 | 0.74 | SIGMAR1 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL3186840 | 0.72 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | SLC6A2 310/4885SLC6A4 261/4885SLC6A3 112/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.